JP2023507584A5 - - Google Patents
Info
- Publication number
- JP2023507584A5 JP2023507584A5 JP2022537550A JP2022537550A JP2023507584A5 JP 2023507584 A5 JP2023507584 A5 JP 2023507584A5 JP 2022537550 A JP2022537550 A JP 2022537550A JP 2022537550 A JP2022537550 A JP 2022537550A JP 2023507584 A5 JP2023507584 A5 JP 2023507584A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical product
- points
- product according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133450A JP2025166121A (ja) | 2019-12-19 | 2025-08-08 | 統合失調症処置方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950828P | 2019-12-19 | 2019-12-19 | |
| US62/950,828 | 2019-12-19 | ||
| PCT/US2020/066224 WO2021127572A1 (en) | 2019-12-19 | 2020-12-18 | Methods of schizophrenia treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133450A Division JP2025166121A (ja) | 2019-12-19 | 2025-08-08 | 統合失調症処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023507584A JP2023507584A (ja) | 2023-02-24 |
| JP2023507584A5 true JP2023507584A5 (enExample) | 2023-12-20 |
| JP7727634B2 JP7727634B2 (ja) | 2025-08-21 |
Family
ID=76437353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537550A Active JP7727634B2 (ja) | 2019-12-19 | 2020-12-18 | 統合失調症処置方法 |
| JP2025133450A Pending JP2025166121A (ja) | 2019-12-19 | 2025-08-08 | 統合失調症処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133450A Pending JP2025166121A (ja) | 2019-12-19 | 2025-08-08 | 統合失調症処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210186962A1 (enExample) |
| EP (2) | EP4744678A3 (enExample) |
| JP (2) | JP7727634B2 (enExample) |
| DK (1) | DK4076461T3 (enExample) |
| ES (1) | ES3067760T3 (enExample) |
| FI (1) | FI4076461T3 (enExample) |
| HR (1) | HRP20260406T1 (enExample) |
| LT (1) | LT4076461T (enExample) |
| PL (1) | PL4076461T3 (enExample) |
| PT (1) | PT4076461T (enExample) |
| RS (1) | RS67890B1 (enExample) |
| SI (1) | SI4076461T1 (enExample) |
| SM (1) | SMT202600134T1 (enExample) |
| WO (1) | WO2021127572A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428506B2 (en) | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| SMT202600133T1 (it) | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| AU2019328528B2 (en) | 2018-08-31 | 2025-01-23 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| IL297333B2 (en) * | 2020-04-17 | 2025-09-01 | Honeybrains Llc | Preparations and methods for treating neuropsychiatric disorders |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000077001A1 (en) | 1999-06-15 | 2000-12-21 | Du Pont Pharmaceuticals Company | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| MX394214B (es) | 2007-03-12 | 2025-03-24 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. |
| CA2719824A1 (en) * | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| ES2530090T3 (es) | 2008-03-12 | 2015-02-26 | Intra-Cellular Therapies, Inc. | Sólido de gamma-carbolinas fusionadas con heterociclo sustituido |
| CA2725342C (en) | 2008-05-27 | 2024-02-20 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders |
| KR102967223B1 (ko) * | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| CA3082834A1 (en) * | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
| WO2019102240A1 (en) * | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020047408A1 (en) * | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020112941A2 (en) * | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
-
2020
- 2020-12-18 LT LTEPPCT/US2020/066224T patent/LT4076461T/lt unknown
- 2020-12-18 EP EP26153433.3A patent/EP4744678A3/en active Pending
- 2020-12-18 SM SM20260134T patent/SMT202600134T1/it unknown
- 2020-12-18 US US17/127,867 patent/US20210186962A1/en active Pending
- 2020-12-18 DK DK20900863.0T patent/DK4076461T3/da active
- 2020-12-18 EP EP20900863.0A patent/EP4076461B1/en active Active
- 2020-12-18 PL PL20900863.0T patent/PL4076461T3/pl unknown
- 2020-12-18 SI SI202030742T patent/SI4076461T1/sl unknown
- 2020-12-18 WO PCT/US2020/066224 patent/WO2021127572A1/en not_active Ceased
- 2020-12-18 ES ES20900863T patent/ES3067760T3/es active Active
- 2020-12-18 RS RS20260344A patent/RS67890B1/sr unknown
- 2020-12-18 PT PT209008630T patent/PT4076461T/pt unknown
- 2020-12-18 FI FIEP20900863.0T patent/FI4076461T3/fi active
- 2020-12-18 HR HRP20260406TT patent/HRP20260406T1/hr unknown
- 2020-12-18 JP JP2022537550A patent/JP7727634B2/ja active Active
-
2025
- 2025-08-08 JP JP2025133450A patent/JP2025166121A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069253B2 (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| DK2694043T3 (en) | COMBINATIONS CONCERNING BREXPIPRAZOL OR A SALT THEREOF AND ANOTHER MEDICINE FOR USE IN TREATING A CNS DISEASE | |
| JP2025166121A5 (enExample) | ||
| CN103945848A (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| FI4076461T3 (fi) | Lumateperoni käytettäväksi skitsofrenian hoidossa | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| KR20200131784A (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 | |
| KR20260048646A (ko) | 엔독시펜을 제조 및 사용하는 방법 | |
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| AU2012326976B2 (en) | Sustained-release preparation | |
| CN112423743A (zh) | 未折叠蛋白反应的激活剂 | |
| JP2024505143A5 (enExample) | ||
| JP2008516925A (ja) | 双極性障害および随伴症状の治療 | |
| HUP0300221A2 (hu) | Oltiprazt tartalmazó készítmények, eljárás az előállításukra, valamint oltipraz alkalmazása májfibrozis és májcirrózis megelőzésére és kezelésére alkalmas gyógyászati készítmények előállítására | |
| Worz et al. | The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins | |
| Murrell et al. | Stribild: a review of component characteristics and combination drug efficacy | |
| CN101180052B (zh) | 含有右旋糖的薄膜包衣制剂 | |
| TWI816718B (zh) | 醫藥調配物 | |
| WO2020247758A1 (en) | Compounds and methods for the treatment of parasitic infections | |
| WO2021155651A1 (zh) | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 | |
| JPWO2020080451A1 (ja) | 糖尿病腎症における腎線維化抑制剤 | |
| CN110891574B (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| JP2023538659A (ja) | Ｏｌｉｇ２阻害剤を用いる併用療法 | |
| JPWO2016117666A1 (ja) | Ｈｉｖ−１感染細胞殺傷剤及びその用途 | |
| JP2014037445A (ja) | 抵抗性統合失調症およびその他のｃｎｓ疾患の治療 |